Ascentage Pharma (AAPG) Q4 2025 earnings review
Core Product Sales Surge, but Absence of Milestone Revenue Drags Down the Bottom Line
Ascentage Pharma executed its commercial strategy aggressively in FY2025. Product sales accelerated by 91% to RMB 499.3M, driven by Olverembatinib's inclusion in China's National Reimbursement Drug List (NRDL) and the successful launch of Lisaftoclax. However, total revenue decoupled from this operational success, decelerating by 41.5% YoY to RMB 574.1M due to the absence of a massive RMB 678.4M IP milestone payment received from Takeda in 2024. Consequently, operating leverage deteriorated, and net loss reversed sharply, widening by 206% to RMB 1.24B. The successful dual-listing on NASDAQ and HKEX follow-on offerings armed the company with RMB 2.47B in cash, providing a solid runway, but the core narrative is a race between scaling commercial revenue and a heavily accelerating cash burn.
🐂 Bull Case
Olverembatinib sales jumped 80.6% to RMB 435.3M (US$62.2M) following NRDL expansion. Lisaftoclax, newly approved in July 2025, generated RMB 70.6M (US$10.1M) in just five months, proving strong market adoption.
A US$132.5M NASDAQ IPO and a US$190.1M HKEX follow-on offering boosted cash and bank balances by 96% to RMB 2.47B (US$353.2M), de-risking the near-term pipeline funding.
🐻 Bear Case
Selling and distribution expenses surged 80.4% to RMB 353.6M, while R&D grew 20.1% to RMB 1.14B. The cost of commercializing new drugs is severely dragging on profitability.
The 41.5% drop in total top-line revenue highlights how dependent Ascentage was on the 2024 Takeda option deal. Recurring product revenue alone is not yet capable of covering the RMB 1.73B combined R&D and SG&A burn.
⚖️ Verdict: ⚪
Neutral. The underlying clinical and commercial momentum is highly impressive and validating for the pipeline. However, the aggressive cash burn and reliance on future capital raises or milestone payments to sustain this expansion warrant caution.
Key Themes
Lisaftoclax (APG-2575) Launch Exceeds Early Expectations
Lisaftoclax launched in late July 2025 as the first Bcl-2 inhibitor conditionally approved in China for CLL/SLL, and only the second globally. Generating RMB 70.6M in its first five months without NRDL coverage implies rapid hospital penetration (328 DTP pharmacies/hospitals entered). Management's plan to push for NRDL inclusion in 2026 could act as a massive volume catalyst, similar to the trajectory of Olverembatinib.
Deep Registrational Pipeline Pipeline Execution
Ascentage is running nine registrational Phase III trials globally. Specifically, Olverembatinib's POLARIS-1 trial in 1L Ph+ ALL and Lisaftoclax's GLORA-4 trial in 1L HR-MDS have both cleared the FDA and EMA. Moving these assets into first-line treatments drastically expands the total addressable market beyond relapsed/refractory settings.
Massive Operating Expense Acceleration
Management narrative heavily touted 2025 as a year of 'remarkable strides' and 'significant execution.' However, this directly contradicts the bottom-line reality: expenses are accelerating violently. Selling & Distribution costs surged 80% to RMB 353.6M, closely mirroring the 91% growth in product sales, meaning commercial leverage has not yet materialized. R&D expenses also rose 20% to RMB 1.14B, pushing the net loss to RMB 1.24B.
Macro Dependency on Chinese NRDL Dynamics
All of Ascentage's commercial revenue currently stems from Mainland China (RMB 574.1M out of total RMB 574.1M). The hyper-growth of Olverembatinib (+81%) was entirely predicated on its inclusion in the Chinese National Reimbursement Drug List (NRDL) effective Jan 2025. While volume scales up, NRDL inclusion traditionally requires steep price cuts. Heavy reliance on Chinese macro healthcare policy remains a risk until US/EU commercialization materializes.
Non-Operating Hits Squeeze Margins
Other expenses accelerated dramatically from RMB 9.1M to RMB 73.6M (up 711%). The primary driver was a RMB 29.5M fair value loss related to contingent consideration from the 2016 acquisition of Guangzhou Healthquest Pharma, plus a sharp increase in donations to RMB 23.4M. These drag heavily on profitability and require monitoring.
Other KPIs
Accelerating liquidity profile. Up 95.9% YoY from RMB 1.26 billion. The successful navigation of capital markets in 2025, securing net proceeds of US$132.5M from the US IPO and US$190.1M from the HK follow-on, provides a comfortable buffer despite the RMB 1.17 billion operating cash outflow.
Accelerating. R&D increased 20.1% YoY from RMB 947.2 million. The internal R&D expenses jumped from RMB 367.9M to RMB 439.6M, while external R&D costs grew from RMB 125.9M to RMB 195.1M, reflecting the heavy clinical burden of running nine simultaneous Phase III trials.
Guidance
Management expects to maintain 'strong growth momentum' driven by their dual-engine commercialization strategy. They plan to pursue NRDL coverage for Lisaftoclax, which implies short-term price compression in exchange for steep volume acceleration in H2 2026.
Key Questions
Lisaftoclax NRDL Strategy and Margins
Lisaftoclax achieved impressive self-pay sales of RMB 70.6M in just five months. As you actively pursue NRDL inclusion for 2026, what magnitude of price concession are you modeling, and how will it impact the gross margin profile compared to Olverembatinib's NRDL ramp?
Commercial Leverage Timeline
Selling and distribution expenses grew at 80% YoY, essentially matching the 81% growth of Olverembatinib. At what revenue run-rate do you expect commercial S&D expenses to decouple from sales growth and provide true operating leverage?
Global Commercialization Strategy
With all 2025 revenue concentrated in China, and POLARIS and GLORA trials advancing globally, what is your ex-China commercialization strategy? Do you intend to build an in-house global sales force, or rely on out-licensing partnerships like the Takeda option agreement?